A nurse is preparing to administer medications to a client who has type 1 diabetes mellitus. The client takes lispro insulin and has a new prescription for pramlintide. Which of the following actions should the nurse take?

Choice A rationale Pramlintide is an amylin analog that helps regulate postprandial glucose levels. One of its known side effects is weight loss, not weight gain. It causes weight loss by promoting a feeling of satiety, which can lead to a reduction in food intake. Therefore, monitoring for weight gain would be an incorrect action; the nurse should actually be monitoring for potential weight loss as a therapeutic or side effect. Choice B rationale Pramlintide can increase the risk of severe hypoglycemia, particularly in clients also taking insulin. However, the peak effect of lispro insulin is typically within 30 to 90 minutes. The risk of hypoglycemia is greatest in the first three hours after administration, especially if the insulin dose is not reduced. Therefore, it is important to be vigilant for hypoglycemia during this period. Choice C rationale The recommended sites for pramlintide injection are the abdomen or thigh. The upper arm is not a standard injection site for pramlintide. The medication is to be injected subcutaneously, and the abdomen or thigh are preferred sites due to their subcutaneous tissue distribution and ease of client access for self-administration. Injections should not be given in the arm. Choice D rationale Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin from the pancreas. It helps regulate glucose levels after a meal. To be effective, it must be administered immediately prior to a major meal (less than 20 minutes before). This timing allows it to slow gastric emptying, suppress glucagon secretion, and promote satiety, which together help to control the postprandial glucose spike. Administering it thirty minutes prior is correct timing.